
Sizheng Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4099582/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study. Rheumatology, 2022, 61, 2043-2053.	0.9	5
2	Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study. Rheumatology International, 2022, 42, 621-629.	1.5	3
3	The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study. Rheumatology, 2022, 61, 2167-2175.	0.9	27
4	Morning Cortisol and Circulating Inflammatory Cytokine Levels: A Mendelian Randomisation Study. Genes, 2022, 13, 116.	1.0	6
5	Genetically Determined Circulating Levels of Cytokines and the Risk of Rheumatoid Arthritis. Frontiers in Genetics, 2022, 13, 802464.	1.1	5
6	ADAMTS5 as a therapeutic target for osteoarthritis: Mendelian randomisation study. Annals of the Rheumatic Diseases, 2022, 81, 903-904.	0.5	6
7	Chronic pain is associated with higher risk of developing and being hospitalized for COVID-19: a Mendelian randomization study. Rheumatology, 2022, 61, SI189-SI190.	0.9	2
8	Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology, 2022, 61, 4678-4686.	0.9	10
9	Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3366-e3373.	1.8	3
10	Genetically predicted vitamin K levels and risk of osteoarthritis: Mendelian randomization study. Seminars in Arthritis and Rheumatism, 2022, 55, 152030.	1.6	3
11	Genetically proxied IL-6 receptor inhibition and risk of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2022, 81, 1480-1482.	0.5	6
12	Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study. Seminars in Arthritis and Rheumatism, 2022, 56, 152058.	1.6	3
13	Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology, 2021, 60, 3189-3198.	0.9	12
14	Comment on: The impact of smoking on prevalence of psoriasis and psoriatic arthritis. Rheumatology, 2021, 60, e26-e26.	0.9	2
15	Anti-TNF biosimilars in rheumatology: the end of an era?. Expert Opinion on Biological Therapy, 2021, 21, 29-36.	1.4	5
16	Google search data as a novel adjunct to patient and public involvement in rheumatology research. Rheumatology International, 2021, 41, 771-779.	1.5	5
17	Versatility of the clone-censor-weight approach: response to "trial emulation in the presence of immortal-time bias― International Journal of Epidemiology, 2021, 50, 694-695.	0.9	9
18	Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology International, 2021, 41, 275-284.	1.5	58

#	Article	IF	CITATIONS
19	Genetically predicted serum urate levels have no causal role on depression or other psychiatric disorders. Clinical Rheumatology, 2021, 40, 3729-3733.	1.0	4
20	Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology, 2021, 60, 5734-5742.	0.9	9
21	P175â€∫Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology, 2021, 60,	0.9	1
22	The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2021, , .	0.9	3
23	P103 Assessment and diagnosis of the acute hot joint: a systematic review and meta-analysis. Rheumatology, 2021, 60, .	0.9	0
24	The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatology International, 2021, 41, 1209-1219.	1.5	23
25	Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: Analysis of the ASAS-perSpA study. Seminars in Arthritis and Rheumatism, 2021, 51, 804-812.	1.6	5
26	Body Fat Composition and Risk of Rheumatoid Arthritis: Mendelian Randomization Study. Arthritis and Rheumatology, 2021, 73, 1943-1944.	2.9	2
27	Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology, 2021, 60, 5795-5800.	0.9	10
28	Why clinicians should know about Mendelian randomization. Rheumatology, 2021, 60, 1577-1579.	0.9	16
29	Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology, 2021, 60, 1620-1628.	0.9	72
30	Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology, 2021, 60, 4158-4165.	0.9	8
31	Diagnosis of spinal tuberculosis in an Asian patient with unexplained chronic back pain. Rheumatology, 2021, , .	0.9	2
32	Global public interest in infectious and non-infectious arthritis: an evaluation using Google Trends. Rheumatology, 2020, 59, 245-246.	0.9	7
33	Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies. Arthritis Care and Research, 2020, 72, 591-599.	1.5	14
34	Incorporating natural language processing to improve classification of axial spondyloarthritis using electronic health records. Rheumatology, 2020, 59, 1059-1065.	0.9	25
35	Systematic review of mental health comorbidities in psoriatic arthritis. Clinical Rheumatology, 2020, 39, 217-225.	1.0	53
36	Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2100-e2100.	1.8	0

#	Article	IF	CITATIONS
37	Comment on: Comorbidity burden in axial spondyloarthritis: a cluster analysis: reply. Rheumatology, 2020, 59, 692-693.	0.9	3
38	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1435-1444.	1.8	26
39	Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology, 2020, 59, iv47-iv57.	0.9	60
40	Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis. Annals of Internal Medicine, 2020, 173, 516-526.	2.0	65
41	P62 Assessing the effect of increased body mass on response to DMARD treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2020, 59, .	0.9	0
42	Comment on: Prevalence of extra-articular manifestations in psoriatic arthritis: reply. Rheumatology, 2020, 59, e51-e53.	0.9	0
43	Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework. Annals of the Rheumatic Diseases, 2020, 79, 883-890.	0.5	14
44	The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis. Rheumatology International, 2020, 40, 1215-1221.	1.5	10
45	COVID-19 and Kawasaki disease: an analysis using Google Trends. Clinical Rheumatology, 2020, 39, 2483-2484.	1.0	12
46	Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology, 2020, 59, 2199-2206.	0.9	41
47	Biologic monotherapy in the biologic naĀ ⁻ ve patient with rheumatoid arthritis (RA): results from an observational study. Rheumatology International, 2020, 40, 1045-1049.	1.5	3
48	Smoking in spondyloarthritis: unravelling the complexities. Rheumatology, 2020, 59, 1472-1481.	0.9	18
49	An update on the general management approach to common vasculitides. Clinical Medicine, 2020, 20, 572-579.	0.8	3
50	Biomarkers for treatment response in rheumatoid arthritis: Where are they?. Rheumatology and Immunology Research, 2020, 1, 1-3.	0.2	3
51	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 177.	1.6	5
52	Response: To statistical significance and beyond. Clinical Rheumatology, 2019, 38, 2285-2286.	1.0	0
53	Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5611-5620.	1.8	28
54	The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101423.	1.4	82

#	Article	IF	CITATIONS
55	O35â€∱Multimorbidity in patients with axial spondyloarthritis: a cluster analysis. Rheumatology, 2019, 58,	0.9	0
56	Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice. Osteoporosis International, 2019, 30, 923-927.	1.3	10
57	Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology, 2019, 58, 2025-2030.	0.9	23
58	Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. Annals of the Rheumatic Diseases, 2019, 78, 1287-1288.	0.5	5
59	Seasonal variations of Google searches for joint swelling: implications for patient-reported outcomes. Clinical Rheumatology, 2019, 38, 1791-1792.	1.0	3
60	Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology, 2019, 58, 1746-1754.	0.9	44
61	Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1753-1765.	1.8	55
62	Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2019, 58, 811-819.	0.9	21
63	Alcohol and disease activity in axial spondyloarthritis: a cross-sectional study. Rheumatology International, 2018, 38, 375-381.	1.5	13
64	Etanercept for the treatment of rheumatoid arthritis. Immunotherapy, 2018, 10, 433-445.	1.0	107
65	Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. Current Rheumatology Reports, 2018, 20, 84.	2.1	29
66	Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology, 2018, 57, 1453-1460.	0.9	53
67	The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Research and Therapy, 2018, 20, 140.	1.6	93
68	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. Current Rheumatology Reports, 2018, 20, 57.	2.1	53
69	309 Comorbid fibromyalgia complicating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and spondyloarthritis: a systematic review and meta-analysis. Rheumatology, 2018, 57, .	0.9	54
70	Biosimilars: From Extrapolation into Off Label Use. Current Pharmaceutical Design, 2018, 23, 6746-6751.	0.9	8
71	Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients. Drugs and Aging, 2017, 34, 255-264.	1.3	22
72	A case of vanishing skull: Gorham's disease. Rheumatology, 2017, 56, 1311-1311.	0.9	0

#	Article	IF	CITATIONS
73	Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcified Tissue International, 2017, 101, 375-383.	1.5	25
74	Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatology International, 2017, 37, 239-244.	1.5	20
75	SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)099.â€∱SMOKING EXPOSURE IS ASSOCIATED WIT INCREASED DISEASE SEVERITY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR ANKYLOSING SPONDYLITIS. Rheumatology, 2017, 56, .	H 0.9	0
76	Vitamin D Deficiency in Axial Spondyloarthritis is Associated With Higher Disease Activity. Archives of Rheumatology, 2017, 32, 209-215.	0.3	14
77	Non-invasive ventilation for sleep-disordered breathing in Smith-Magenis syndrome. BMJ Case Reports, 2016, 2016, bcr2016215621.	0.2	4
78	200 Autoantibodies to Osteoprotegerin and Bone Mineral Density in Axial Spondyloarthritis. Rheumatology, 2016, , .	0.9	0
79	Diffuse idiopathic skeletal hyperostosis and isotretinoin in cystic acne. BMJ Case Reports, 2015, 2015, bcr2015209775.	0.2	9
80	Vitamin D assessment in primary care: changing patterns of testing. London Journal of Primary Care, 2015, 7, 15-22.	0.9	35
81	Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive Neuromyelitis Optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2015, 4, 614-618.	0.9	31
82	Smoking and comorbidities in rheumatoid arthritis: what we know and what we can do?. International Journal of Clinical Rheumatology, 2015, 10, 45-53.	0.3	1
83	An unusual case of 'itchy paralysis': neuromyelitis optica presenting with severe neuropathic itch. Practical Neurology, 2015, 15, 149-151.	0.5	6
84	Increased Mortality Amongst Patients Sustaining Neck of Femur Fractures as In-Patients in a Trauma Centre. The Open Orthopaedics Journal, 2015, 9, 412-417.	0.1	5
85	Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Multiple Sclerosis Journal, 2014, 20, 1658-1661.	1.4	63
86	Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. Rheumatology, 2014, 53, 1595-1603.	0.9	43
87	PAIN IN NEUROMYELITIS OPTICA IS AN UNDER–RECOGNISED BUT DISABLING SYMPTOM. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.107-e2.	0.9	1
88	Deafness: malaria as a forgotten cause. Annals of Tropical Paediatrics, 2011, 31, 1-10.	1.0	23
89	Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception?. Clinical and Experimental Rheumatology, 0, , .	0.4	7